Investing.com - Zealand Pharma (NASDAQ:ZEAL) ADR reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Zealand Pharma ADR announced earnings per share of kr-1.54 on revenue of kr3.95M. Analysts polled by Investing.com anticipated EPS of kr-1.11 on revenue of kr4.51M.
Zealand Pharma ADR shares are up 20.98% from the beginning of the year, still down 49.04% from its 52 week high of kr34.30 set on September 24, 2021. They are outperforming the Nasdaq which is down 18.31% from the start of the year.
Zealand Pharma ADR follows other major Healthcare sector earnings this month
Zealand Pharma ADR's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of kr5.57 on revenue of kr80.33B, compared to forecasts EPS of kr5.21 on revenue of kr79.68B.
J&J had beat expectations on July 19 with second quarter EPS of kr2.59 on revenue of kr24.02B, compared to forecast for EPS of kr2.54 on revenue of kr23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar